Foghorn Therapeutics Incis A Clinical Stage Biotechnology Company Based In Cambridgemassachusettsthe Company Focuses On Developing Precision Medicines That Target The Chromatin Regulatory System To Address Diseases Caused By Abnormal Gene Expressionparticularly In Oncologyfoghorn Utilizes Its Proprietary Gene Traffic Controlaplatform To Create Therapies That Modulate Gene Activity By Remodeling The 3D Structure Of Dna Foghorn Has Advanced Nearly 10 Programswith Key Candidates In Clinical Trialsnotable Products Include Fhd 286Which Targets Brm Brg1 Proteins For Hematologic Malignancies And Solid Tumorsand Fhd 609A Brd9 Inhibitor Currently In Phase I Trials For Synovial Sarcomathe Company Also Has Preclinical Programs Aimed At Additional Chromatin Related Dependenciesfoghorn S Mission Is To Transform Lives By Addressing The Root Causes Of Gene Expression Related Diseaseswith A Focus On Oncology And Potential Applications In Other Disorders
